Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | B LAL & SONS | 1 | ₹5,400 |
| 2 | Schedule 2 | ADOKAN PHARMA | 1 | ₹2,600 |
| 3 | Schedule 3 | SUKUN PHARMA | 1 | ₹45,600 |
| 4 | Schedule 4 | SRI SAI AGENCIES | 1 | ₹9,450 |
| 5 | Schedule 5 | ADOKAN PHARMA | 1 | ₹8,800 |
Tender Value
₹73,125
EMD Value
Exempted
Closing Date
20 Mar 2025, 6:00 pmClosed
Nitrofurantion 100 mg Tablet
Cilnidipine 10 mg Tablet
Merabegron 50 mg Tablet
Solifenacin 5 mg Tablet
Glucosamine 500 mg Tablet
7582548
GEM/2025/B/6002892
Two Packet Bid
Cilnidipine 10 mg Tablet
20 days
Uttar Pradesh; Kanpur Nagar
Item wise evaluation
BOQ
8 documents required · 8 mandatory
3 yrs
₹31
80%
Exempted
20 Mar 2025
27 Feb 2025
20 Mar 2025
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) | Spec |
|---|---|---|---|---|---|---|
| 1 | Nitrofurantion 100 mg Tablet | 6,000 | Number | KANPUR CITY | 20 | |
| 2 | Cilnidipine 10 mg Tablet | 10,000 | Number | KANPUR CITY | 20 | |
| 3 | Merabegron 50 mg Tablet | 12,000 | Number | KANPUR CITY | 20 | |
| 4 | Solifenacin 5 mg Tablet | 5,000 | Number | KANPUR CITY | 20 | - |
| 5 | Glucosamine 500 mg Tablet | 20,000 | Number | KANPUR CITY | 20 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7582548.pdf
GEM_BID
specification_2025-02-27-15-58-23_a4eb40552695891e6d37795dd8e07d85.pdf
BOQ
boq_item_sample_file_2025-02-27-15-58-23_31e2eb049ec762e97089f04d31b6ea21.csv
BOQ
CertI_bbfc8014-47aa-4234-a20e1740655990496_7AFHMEDSTR.docx
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .